Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years

the UK Aflibercept Users’ Group, S. J. Talks, I. Stratton, T. Peto, A. Lotery, U. Chakravarthy, Haralabos Eleftheriadis, S. Izadi, Naren Dhingra, P. Scanlon, James Talks, P. Scanlon, Quresh Mohamed, Andrew Lotery, Sharam Kashani, Nasos Georgas, Colin Jones, Abdisattar Gashut, Cynthia Santiago, Romi ChhabraRichard Antcliff, Naren Dhingra, Clare Bailey, U. Chakravarthy, Faruque Ghanchi, Linda Mcinerney, Salim Natha, Rehna Khan, Indra Dias, Raj Mukhrejee, Shahrnaz Izadi, Irfan Tahir, Haralabos Eleftheriadis

Research output: Contribution to journalArticlepeer-review

25 Downloads (Pure)


Introduction: Randomised controlled trials provide evidence that a treatment works. Real world evidence is required to assess if proven treatments are effective in practice. 

Method: Retrospective data collection on patients given aflibercept for diabetic macular oedema over 3 years from 21 UK hospitals: visual acuity (VA); Index of multiple deprivation score (IMD); injection numbers; protocols used, compared as a cohort and between sites. 

Results: Complete data: 1742 patients (from 2196 eligible) at 1 year, 860 (from 1270) at 2, 305 (from 506) at 3 years. The median VA improved from 65 to 71, 70, 70 (ETDRS letters) at 1, 2 and 3 years with 6, 9 and 12 injections, respectively. Loss to follow-up: 10% 1 year, 28.8% at 3. Centres varied: baseline: mean age 61–71 years (p < 0.0001); mean IMD score 15–37 (p < 0.0001); mean VA 49–68 (p < 0.0001). Only four centres provided a loading course of five injections at monthly intervals and one 6. This did not alter VA outcome at 1 year. Higher IMD was associated with younger age (p = 0.0023) and worse VA at baseline (p < 0.0001) not total number of injections or change in VA. Lower starting VA, higher IMD and older age were associated with lower adherence (p = 0.0010). 

Conclusions: The data showed significant variation between treatment centres for starting age, VA and IMD which influenced adherence and chances of good VA. Once treatment was started IMD did not alter likelihood of improvement. Loading dose intensity did not alter outcome at one year.

Original languageEnglish
Pages (from-to)72–77
Publication statusPublished - 09 Jul 2021
Externally publishedYes

Bibliographical note

Funding Information:
SJT: Research and Advisory boards for Bayer; Novartis; Roche; Allergan; Alimera; IS: Consultant for Novo Nordisk; TP: Speaker and advisory board Bayer, Novartis, Roche; AL: None; UC: Chair of International trials sponsored by Bayer; HE: Research and Travel Bayer; SI: Research Bayer; travel Bayer and Novartis; ND: Research Novartis; Travel Novartis; Allergan; Bayer; Speaker Novartis; Advisory Board Novartis; PS: Research and audit grants from Allergan, Boehringer, Novartis, Bayer; Advisory Boards for Pfizer; Allergan; Roche; Boehringer and Bayer.

Publisher Copyright:
© 2021, The Author(s).

Copyright 2021 Elsevier B.V., All rights reserved.


  • eye
  • diabetic retinopathy
  • treatment

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems


Dive into the research topics of 'Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years'. Together they form a unique fingerprint.

Cite this